Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Study Summary

This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.

Conditions

Ovarian Cancer Hepatocellular Carcinoma Non-small Cell Lung Cancer Bladder Cancer Microsatellite Instability-High

Interventions / Drugs

DPX-Survivac Cyclophosphamide Pembrolizumab

View on ClinicalTrials.gov ↗

Sponsor

IMV

IMV Inc

DPX Immunotherapy Platform

C61/100

Study Details

Enrollment184 participants

Primary Completion—

Lead SponsorImmunoVaccine Technologies, Inc. (IMV Inc.)

Data Retrieved2026-04-11 04:17:09.517945+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.